1
|
Sun A, Xing Z, Lv R, Niu P, Zhao B, Ma S, Li H. Research progress of immunotherapy for advanced head and neck cancer. Med Oncol 2024; 41:133. [PMID: 38703250 DOI: 10.1007/s12032-024-02375-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2024] [Accepted: 03/28/2024] [Indexed: 05/06/2024]
Abstract
Head and neck cancer accounts for about one-fifth of all malignant tumors, and the incidence is increasing year by year. The overall mortality rate was high and the 5-year survival rate was low. At present, the combination of surgery, radiotherapy, and chemotherapy is the main treatment in clinical practice, but the treatment of recurrent or metastatic advanced head and neck cancer is still a challenge. With the rise of immunotherapy, more and more studies on immune checkpoint inhibitors have been conducted. This review summarizes the mechanism, clinical application and safety of immunotherapy for advanced head and neck cancer.
Collapse
Affiliation(s)
- Anchi Sun
- Department of Otolaryngology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, 233004, Anhui, China
- Anhui Engineering Technology Research Center of Biochemical Pharmaceutical, 2600 Donghai Avenue, Bengbu, 233030, Anhui, China
| | - Zhiwei Xing
- Department of Otolaryngology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, 233004, Anhui, China
| | - Rongrong Lv
- Department of Otolaryngology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, 233004, Anhui, China
| | - Pengyuan Niu
- Department of Neurosurgery, The First Affiliated Hospital of Bengbu Medical University, Bengbu, 233004, Anhui, China
| | - Bao Zhao
- Department of Otolaryngology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, 233004, Anhui, China
- Institute of Health and Medicine, Hefei Comprehensive National Science Center, Hefei, 230071, Anhui, China
| | - Shiyin Ma
- Department of Otolaryngology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, 233004, Anhui, China.
| | - Hui Li
- Department of Otolaryngology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, 233004, Anhui, China.
| |
Collapse
|
2
|
Kitano S, Shimizu T, Koyama T, Ebata T, Iwasa S, Kondo S, Shimomura A, Fujiwara Y, Yamamoto N, Paccaly A, Li S, Rietschel P, Sims T. Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies. Cancer Chemother Pharmacol 2021; 87:53-64. [PMID: 33146741 PMCID: PMC7801352 DOI: 10.1007/s00280-020-04161-6] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2020] [Accepted: 09/30/2020] [Indexed: 12/19/2022]
Abstract
PURPOSE Part 1 of this two-part, open-label, Phase 1 study (NCT03233139) assessed the safety, tolerability, pharmacokinetics, immunogenicity, and clinical activity of cemiplimab in Japanese patients with advanced malignancies. METHODS Patients received cemiplimab 250 mg (n = 6) or 350 mg (n = 7) every 3 weeks intravenously for up to 108 weeks in Part 1. Tumor responses were assessed by investigators every 9 weeks using the Response Evaluation Criteria in Solid Tumors version 1.1. RESULTS Of 13 patients enrolled, median age was 62 years (range 33-75) and eight patients were female. Median duration of cemiplimab exposure was 13.1 weeks (range 3.0‒113.6). At the time of data cut-off, 11 patients (84.6%) had discontinued treatment (majority due to disease progression: n = 8, 61.5%). The most common treatment-emergent adverse events (TEAEs) of any grade were contact dermatitis, rash, and viral upper respiratory tract infection (each n = 3, 23.1%). Five grade ≥ 3 TEAEs were reported in four patients: autoimmune colitis, dehydration, hyponatremia, hypophosphatemia, and muscular weakness. No dose-limiting toxicities were reported and no TEAEs led to death. Cemiplimab concentrations in serum were consistent with previously reported pharmacokinetic characteristics of cemiplimab. No anti-drug antibodies were detected in serum. Objective response rate [ORR; complete response + partial response (PR)] was 30.8% (four PR) and disease control rate [ORR + stable disease (SD)] was 46.2% (6/13; two SD). CONCLUSION Cemiplimab exhibited antitumor activity in Japanese patients with advanced malignancies. The safety profile was comparable to those previously reported for cemiplimab and other PD-1 inhibitors. TRIAL REGISTRATION NCT03233139 at ClinicalTrials.gov.
Collapse
MESH Headings
- Administration, Intravenous
- Adult
- Aged
- Antibodies, Monoclonal, Humanized/administration & dosage
- Antibodies, Monoclonal, Humanized/adverse effects
- Antibodies, Monoclonal, Humanized/pharmacokinetics
- Antineoplastic Agents, Immunological/administration & dosage
- Antineoplastic Agents, Immunological/adverse effects
- Antineoplastic Agents, Immunological/pharmacokinetics
- Disease Progression
- Dose-Response Relationship, Drug
- Female
- Humans
- Japan
- Male
- Middle Aged
- Neoplasms/drug therapy
- Neoplasms/pathology
- Response Evaluation Criteria in Solid Tumors
Collapse
Affiliation(s)
- Shigehisa Kitano
- Department of Experimental Therapeutics Koto-ku, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
| | - Toshio Shimizu
- Department of Experimental Therapeutics Koto-ku, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan
| | - Takafumi Koyama
- Department of Experimental Therapeutics Koto-ku, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan
| | - Takahiro Ebata
- Department of Experimental Therapeutics Koto-ku, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan
| | - Satoru Iwasa
- Department of Experimental Therapeutics Koto-ku, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan
| | - Shunsuke Kondo
- Department of Experimental Therapeutics Koto-ku, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan
| | - Akihiko Shimomura
- Department of Experimental Therapeutics Koto-ku, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan
| | - Yutaka Fujiwara
- Department of Experimental Therapeutics Koto-ku, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan
| | - Noboru Yamamoto
- Department of Experimental Therapeutics Koto-ku, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan
| | - Anne Paccaly
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
| | - Siyu Li
- Regeneron Pharmaceuticals, Inc., Basking Ridge, NJ, USA
| | | | - Tasha Sims
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA
| |
Collapse
|
3
|
van Vugt MJH, Stone JA, De Greef RHJMM, Snyder ES, Lipka L, Turner DC, Chain A, Lala M, Li M, Robey SH, Kondic AG, De Alwis D, Mayawala K, Jain L, Freshwater T. Immunogenicity of pembrolizumab in patients with advanced tumors. J Immunother Cancer 2019; 7:212. [PMID: 31395089 PMCID: PMC6686242 DOI: 10.1186/s40425-019-0663-4] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2019] [Accepted: 07/04/2019] [Indexed: 12/25/2022] Open
Abstract
Background Pembrolizumab is a potent, humanized, monoclonal anti–programmed death 1 antibody that has demonstrated effective antitumor activity and acceptable safety in multiple tumor types. Therapeutic biologics can result in the development of antidrug antibodies (ADAs), which may alter drug clearance and neutralize target binding, potentially reducing drug efficacy; such immunogenicity may also result in infusion reactions, anaphylaxis, and immune complex disorders. Pembrolizumab immunogenicity and its impact on exposure, safety, and efficacy was assessed in this study. Patients and methods Pembrolizumab immunogenicity was assessed in 3655 patients with advanced or metastatic cancer treated in 12 clinical studies. Patients with melanoma, non–small cell lung cancer, head and neck squamous cell carcinoma, colorectal cancer, urothelial cancer, and Hodgkin lymphoma were treated with pembrolizumab at 2 mg/kg every 3 weeks, 10 mg/kg every 2 weeks, 10 mg/kg every 3 weeks, or 200 mg every 3 weeks. An additional study involving 496 patients with stage III melanoma treated with 200 mg adjuvant pembrolizumab every 3 weeks after complete resection was analyzed separately. Results Of 3655 patients, 2000 were evaluable for immunogenicity analysis, 36 (1.8%) were treatment-emergent (TE) ADA-positive; 9 (0.5%) of these TE-positive patients had antibodies with neutralizing capacity. The presence of pembrolizumab-specific ADAs did not impact pembrolizumab exposure, nor did pembrolizumab immunogenicity affect the incidence of drug-related adverse events (AEs) or infusion-related reactions. There was no clear relationship between the presence of pembrolizumab-specific ADAs and changes in tumor size across treatment regimens. Of the 496 patients treated with pembrolizumab as adjuvant therapy, 495 were evaluable, 17 (3.4%) were TE ADA–positive; none had neutralizing antibodies. Conclusions The incidence of TE (neutralizing positive) ADAs against pembrolizumab was low in patients with advanced tumors. Furthermore, immunogenicity did not appear to have any clinically relevant effects on the exposure, safety, or efficacy of pembrolizumab. Trial registration ClinicalTrials.gov, NCT01295827 (February 15, 2011), NCT01704287 (October 11, 2012), NCT01866319 (May 31, 2013), NCT01905657 (July 23, 2013), NCT02142738 (May 20, 2014), NCT01848834 (May 8, 2013), NCT02255097 (October 2, 2014), NCT02460198 (June 2, 2015), NCT01953692 (October 1, 2013), NCT02453594 (May 25, 2015), NCT02256436 (October 3, 2014), NCT02335424 (January 9, 2015), NCT02362594 (February 13, 2015). Electronic supplementary material The online version of this article (10.1186/s40425-019-0663-4) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
| | - Julie A Stone
- Quantitative Pharmacology, Merck & Co., Inc, Kenilworth, NJ, USA
| | | | - Ellen S Snyder
- Quantitative Pharmacology, Merck & Co., Inc, Kenilworth, NJ, USA
| | - Leslie Lipka
- Quantitative Pharmacology, Merck & Co., Inc, Kenilworth, NJ, USA
| | - David C Turner
- Quantitative Pharmacology, Merck & Co., Inc, Kenilworth, NJ, USA
| | - Anne Chain
- Quantitative Pharmacology, Merck & Co., Inc, Kenilworth, NJ, USA
| | - Mallika Lala
- Quantitative Pharmacology, Merck & Co., Inc, Kenilworth, NJ, USA
| | - Mengyao Li
- Quantitative Pharmacology, Merck & Co., Inc, Kenilworth, NJ, USA
| | - Seth H Robey
- Quantitative Pharmacology, Merck & Co., Inc, Kenilworth, NJ, USA
| | | | - Dinesh De Alwis
- Quantitative Pharmacology, Merck & Co., Inc, Kenilworth, NJ, USA
| | - Kapil Mayawala
- Quantitative Pharmacology, Merck & Co., Inc, Kenilworth, NJ, USA
| | - Lokesh Jain
- Quantitative Pharmacology, Merck & Co., Inc, Kenilworth, NJ, USA
| | | |
Collapse
|
4
|
Lloret M, García-Cabrera L, Hernandez A, Santana N, López-Molina L, Lara PC. Feasibility of a deep hyperthermia and radiotherapy programme for advanced tumors: first Spanish experience. Clin Transl Oncol 2019; 21:1771-1775. [PMID: 31102061 DOI: 10.1007/s12094-019-02097-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2019] [Accepted: 03/20/2019] [Indexed: 11/26/2022]
Abstract
BACKGROUND Hyperthermia (HT) is used to increase the temperature of the tumor-sensitizing cells to the effects of radiation/chemotherapy. We aimed to assess the feasibility, tolerability and safety of hyperthermia treatment in a Radiation Oncology Department. METHODS Between June 2015 and June 2017, 106 patients and a total of 159 tumor lesions were included in a prospective study (EudraCT 2018-001089-40) of HT concomitant with radiotherapy (RT). Systemic treatment was accepted. HT was given twice a week, 60 min per session, during RT treatment by a regional capacitive device (HY-DEEP 600WM system) at 13.56 MHz radiofrequency. RESULTS Most lesions (138 cases, 86.8%) received all HT sessions planned. Thirteen lesions (12 patients) withdrew treatment due to grade ≥3 QMHT toxicity. All these 12 patients completed the prescribed radiotherapy and/or systemic treatment. CONCLUSIONS Regional hyperthermia is a feasible and safe technique to be used in combination with radiotherapy and systemic treatment.
Collapse
Affiliation(s)
- M Lloret
- Department of Radiation Oncology, Dr. Negrin Hospital, Barranco de la Ballena s/n, 35010, Las Palmas de Gran Canaria, Spain.
- Universidad de Las Palmas de Gran Canaria, Las Palmas, Spain.
- Instituto Canario de Investigación del Cáncer, Las Palmas de Gran Canaria, Spain.
| | - L García-Cabrera
- Department of Radiation Oncology, Dr. Negrin Hospital, Barranco de la Ballena s/n, 35010, Las Palmas de Gran Canaria, Spain
| | - A Hernandez
- Department of Radiation Oncology, Dr. Negrin Hospital, Barranco de la Ballena s/n, 35010, Las Palmas de Gran Canaria, Spain
| | - N Santana
- Department of Radiation Oncology, Dr. Negrin Hospital, Barranco de la Ballena s/n, 35010, Las Palmas de Gran Canaria, Spain
| | - L López-Molina
- Department of Radiation Oncology, Dr. Negrin Hospital, Barranco de la Ballena s/n, 35010, Las Palmas de Gran Canaria, Spain
| | - P C Lara
- Instituto Canario de Investigación del Cáncer, Las Palmas de Gran Canaria, Spain
- Universidad Fernando Pessoa Canarias, Las Palmas, Spain
- Hospital Universitario San Roque, Las Palmas, Spain
| |
Collapse
|